Literature DB >> 22112599

HIV infection and risk of overdose: a systematic review and meta-analysis.

Traci C Green1, Samuel K McGowan, Michael A Yokell, Enrique R Pouget, Josiah D Rich.   

Abstract

Drug overdose is a common cause of non-AIDS death among people with HIV and the leading cause of death for people who inject drugs. People with HIV are often exposed to opioid medications during their HIV care experience; others may continue to use illicit opioids despite their disease status. In either situation, there may be a heightened risk for nonfatal or fatal overdose. The potential mechanisms for this elevated risk remain controversial. We systematically reviewed the literature on the HIV-overdose association, meta-analyzed results, and investigated sources of heterogeneity, including study characteristics related to hypothesize biological, behavioral, and structural mechanisms of the association. Forty-six studies were reviewed, 24 of which measured HIV status serologically and provided data quantifying an association. Meta-analysis results showed that HIV seropositivity was associated with an increased risk of overdose mortality (pooled risk ratio 1.74, 95% confidence interval 1.45, 2.09), although the effect was heterogeneous (Q = 80.3, P < 0.01, I(2) = 71%). The wide variability in study designs and aims limited our ability to detect potentially important sources of heterogeneity. Causal mechanisms considered in the literature focused primarily on biological and behavioral factors, although evidence suggests structural or environmental factors may help explain the greater risk of overdose among HIV-infected drug users. Gaps in the literature for future research and prevention efforts as well as recommendations that follow from these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22112599      PMCID: PMC3329893          DOI: 10.1097/QAD.0b013e32834f19b6

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  97 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Associations of sex ratios and male incarceration rates with multiple opposite-sex partners: potential social determinants of HIV/STI transmission.

Authors:  Enrique R Pouget; Trace S Kershaw; Linda M Niccolai; Jeannette R Ickovics; Kim M Blankenship
Journal:  Public Health Rep       Date:  2010 Jul-Aug       Impact factor: 2.792

Review 3.  Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection.

Authors:  Linda R Gowing; Michael Farrell; Reinhard Bornemann; Lynn E Sullivan; Robert L Ali
Journal:  J Gen Intern Med       Date:  2005-12-07       Impact factor: 5.128

4.  Non-fatal overdose and subsequent drug treatment among injection drug users.

Authors:  Robin A Pollini; Lisa McCall; Shruti H Mehta; David Vlahov; Steffanie A Strathdee
Journal:  Drug Alcohol Depend       Date:  2005-11-23       Impact factor: 4.492

5.  Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study.

Authors:  Marina Davoli; Anna M Bargagli; Carlo A Perucci; Patrizia Schifano; Valeria Belleudi; Matthew Hickman; Giuseppe Salamina; Roberto Diecidue; Federica Vigna-Taglianti; Fabrizio Faggiano
Journal:  Addiction       Date:  2007-12       Impact factor: 6.526

6.  The shifting pattern of cause-specific mortality in a cohort of human immunodeficiency virus-infected and non-infected injecting drug users.

Authors:  Inmaculada Ferreros; Blanca Lumbreras; Isabel Hurtado; Santiago Pérez-Hoyos; Ildefonso Hernández-Aguado
Journal:  Addiction       Date:  2008-04       Impact factor: 6.526

7.  Mortality among injection drug users in Chennai, India (2005-2008).

Authors:  Sunil S Solomon; David D Celentano; Aylur K Srikrishnan; Canjeevaram K Vasudevan; Santhanam Anand; Muniratnam S Kumar; Suniti Solomon; Gregory M Lucas; Shruti H Mehta
Journal:  AIDS       Date:  2009-05-15       Impact factor: 4.177

8.  A micro-environmental intervention to reduce the harms associated with drug-related overdose: evidence from the evaluation of Vancouver's safer injection facility.

Authors:  Thomas Kerr; Will Small; David Moore; Evan Wood
Journal:  Int J Drug Policy       Date:  2007-01-16

9.  The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.

Authors:  Perrine Roux; M Patrizia Carrieri; Virgine Villes; Pierre Dellamonica; Isabelle Poizot-Martin; Isabelle Ravaux; Bruno Spire
Journal:  Addiction       Date:  2008-09-04       Impact factor: 6.526

10.  Factors associated with premature mortality among young injection drug users in Vancouver.

Authors:  Cari L Miller; Thomas Kerr; Steffanie A Strathdee; Kathy Li; Evan Wood
Journal:  Harm Reduct J       Date:  2007-01-04
View more
  46 in total

1.  Correlates of overdose risk perception among illicit opioid users.

Authors:  Christopher Rowe; Glenn-Milo Santos; Emily Behar; Philip O Coffin
Journal:  Drug Alcohol Depend       Date:  2015-12-30       Impact factor: 4.492

2.  Factors Associated with State Variation in Mortality Among Persons Living with Diagnosed HIV Infection.

Authors:  Amy L Krueger; Michelle Van Handel; Patricia M Dietz; Weston O Williams; Anna Satcher Johnson; Pamela W Klein; Stacy Cohen; Paul Mandsager; Laura W Cheever; Philip Rhodes; David W Purcell
Journal:  J Community Health       Date:  2019-10

3.  Clinical risk factors for death after release from prison in Washington State: a nested case-control study.

Authors:  Ingrid A Binswanger; Marc F Stern; Traci E Yamashita; Shane R Mueller; Travis P Baggett; Patrick J Blatchford
Journal:  Addiction       Date:  2016-03       Impact factor: 6.526

4.  Drugs, discipline and death: Causes and predictors of mortality among people who inject drugs in Tijuana, 2011-2018.

Authors:  Brooke S West; Daniela A Abramovitz; Patricia Gonzalez-Zuniga; Gudelia Rangel; Dan Werb; Javier Cepeda; Leo Beletsky; Steffanie A Strathdee
Journal:  Int J Drug Policy       Date:  2019-11-24

Review 5.  Novel interventions to prevent HIV and HCV among persons who inject drugs.

Authors:  Phillip O Coffin; Christopher Rowe; Glenn-Milo Santos
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

6.  Pharmacotherapy, Resource Needs, and Physician Recruitment Practices in Substance Use Disorder Treatment Programs.

Authors:  Hannah K Knudsen; Randy Brown; Nora Jacobson; Julie Horst; Jee-Seon Kim; Elizabeth Collier; Sanford Starr; Lynn M Madden; Eric Haram; Todd Molfenter
Journal:  J Addict Med       Date:  2019 Jan/Feb       Impact factor: 3.702

7.  Polypharmacy and risk of non-fatal overdose for patients with HIV infection and substance dependence.

Authors:  Theresa W Kim; Alexander Y Walley; Timothy C Heeren; Gregory J Patts; Alicia S Ventura; Gabriel B Lerner; Nicholas Mauricio; Richard Saitz
Journal:  J Subst Abuse Treat       Date:  2017-07-14

8.  No association between HIV status and risk of non-fatal overdose among people who inject drugs in Vancouver, Canada.

Authors:  Daniel J Escudero; Brandon D L Marshall; Thomas Kerr; Kanna Hayashi; Cindy Feng; Silvia A Guillemi; Robert S Hogg; Julio Montaner; Evan Wood; M-J Milloy
Journal:  Addict Behav       Date:  2016-04-01       Impact factor: 3.913

9.  The impact of prescribed opioids on CD4 cell count recovery among HIV-infected patients newly initiating antiretroviral therapy.

Authors:  E J Edelman; K S Gordon; J P Tate; W C Becker; K Bryant; K Crothers; J R Gaither; C L Gibert; A J Gordon; Bdl Marshall; M C Rodriguez-Barradas; J H Samet; M Skanderson; A C Justice; D A Fiellin
Journal:  HIV Med       Date:  2016-11       Impact factor: 3.180

Review 10.  Synaptic dysfunction in human immunodeficiency virus type-1-positive subjects: inflammation or impaired neuronal plasticity?

Authors:  V Avdoshina; A Bachis; I Mocchetti
Journal:  J Intern Med       Date:  2013-05       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.